Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21Standard of Care 20Sirolimus 20Azacitidine 20venetoclax 19Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × SNX-5422 × Clear all
NCT01635712 2017-04-26

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Esanex Inc.

Phase 1 Completed
10 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT00595686 2012-05-17

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Esanex Inc.

Phase 1 Completed
25 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡